Former EVP, Research and Development · CRISPR Therapeutics AG (CRSP)

Tony Ho

A named executive officer of CRISPR Therapeutics in every fiscal year CompBrief holds from FY2017 to FY2021. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$6,523,643

Salary $467,000Stock awards $1,204,920

FY2020: $3,890,244

3rd of 6 named executive officers at Crispr Therapeutics by FY2021 total.

6 named officers on file for CRISPR Therapeutics, FY2021

Tony Ho’s pay file — $29

  • 5 fiscal years of pay, line by line
  • CRSP’s disclosed peer group of 19 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how CRISPR Therapeutics’s whole pay program stands against its peers

  • CRISPR Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on CRSP→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 25, 2022 (DEF 14A).

Free

Get Tony Ho’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Tony Ho compensation by year

CRISPR Therapeutics Summary Compensation Table · all 5 fiscal years held
In US dollars, as CRISPR Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2017FY2018FY2019FY2020FY2021
Salary$170,833$414,980$431,575$451,000$467,000
Bonus$100,000$0$0$0$0
Stock awards$1,267,500$0$3,333,900$614,213$1,204,920
Option awards$2,843,484$3,466,188$1,948,674$2,368,031$2,787,434
Non-equity incentive$92,199$258,321$281,603$288,189$210,150
Pension and deferred compensation$0$0$0$0$0
All other$0$9,625$9,800$168,811$1,854,139
Total$4,474,016$4,149,115$6,005,552$3,890,244$6,523,643

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: CRISPR Therapeutics AG DEF 14A filed April 25, 2022, accession 0000950170-22-006098, and prior-year filings.

How this page was built: the CRISPR Therapeutics AG filed document, accession 0000950170-22-006098. Every figure is read from that document and cited to the page and table it appears in. Filed April 25, 2022.

$4.5M
$4.1M
$6.0M
$3.9M
$6.5M
FY17
FY18
FY19
FY20
FY21
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
RSU13,333$1,010,375—
RSU9,167$694,675—
RSU9,000$682,020—
RSU3,334$252,651—
Option11,806—$86.75
Option13,225—$97.00
Option18,959—$133.88
Option3,313—$51.49
Option5,375—$59.31
Option23,438—$40.87
Option30,938—$44.67

Per the Outstanding Equity Awards at Fiscal Year-End table in CRISPR Therapeutics AG's FY2021 proxy; value at the fiscal year-end close, as the company printed it.

CRISPR Therapeutics’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
Samarth KulkarniChief Executive Officer$17,037,015
Brendan SmithFormer Chief Financial Officer$7,345,040
Tony Ho · this pageFormer EVP, Research and Development$6,523,643
Lawrence KleinFormer Chief Operating Officer$5,960,500
James KasingerGeneral Counsel$4,642,761
Michael TomsicekFormer Chief Financial Officer$3,760,766

The full CRISPR Therapeutics compensation record

free company brief

This page is one person within CRISPR Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are CRISPR Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Tony Ho's compensation dossier · One-time report. No refunds.